23.08.2011
AUGUST 23, 2011, MOSCOW – OJSC «VEROPHARM» [RTS:VRPH, MICEX:VFRM] announces preliminary data and operational performance indicators for the first half of 2011 year according to the management accounting.
In H1 2011 sales of Veropharm’s finished goods increased by 18% compared to the same period in 2010, reaching RUR 3,154.8 million. [1]
- Rx drugs sales amounted to RUR 2,189.4 million in H1 2011, a 16,4% inecrease in comparison with H1 2010. The Rx drugs sales accounted for 69,4% of total finished goods sales.[2]
- OTC drugs sales amounted to RUR 392.6 million in H1 2011, a 32,2% increase in comparison with H1 2010. The share of OTC drugs sales accounted for 12,5% of total finished goods sales.
- In H1 2011 traditional drug sales amounted to RUR 13.7 million, which represents 55,1% decrease as compared to H1 2010, and made up 0,4% of total finished goods sales.
- Adhesive bandages and cosmetic products sales came to RUR 559.1 million, a 20,3% increase in comparison with H1 2010. The share of adhesive bandages and cosmetic products in total finished goods sales of the Company was 17,7%.
Veropharm sales as part of the Federal Reimbursement Program (FRP) came to RUR 79,1 million, accounting for 2,5% of the Company’s total finished goods sales.[2]
In H1 2011 sales in Russian Federation provide 97% of the Ñompany’s sales. In H1 2011 exports accounted for 3% of the Company’s total finished goods sales compared to 2% in H1 2010.
Rx drugs segmentTotal sales of the five most popular prescription drugs by the results in H1 2011 amounted to RUR 803.1 million, or 36% of sales in the prescription drugs segment and 25% of the Company’s total finished goods sales [2].
The five top-selling Rx drugs in H1 2011 results include:
- Irunine (Itraconazole; ATC[3] «General anti-infectives systemic»); sales growth in comparison with H1 2011 amounted 98%; 10% of sales in the prescription drugs segment;
- Cerepro (Holina Alfostserat; ATC «Central nervous system»); sales growth in comparison with H1 2011 amounted 42%; 9% of sales in the prescription drugs segment;
- Geptor (Ademetionine; ATC«Digestive tract and metabolism»); sales growth in comparison with H1 2011 amounted 57%; 7% of sales in the prescription drugs segment;
- Amigrenin (Sumatriptan; ATC «Central nervous system»); sales growth in comparison with H1 2011 amounted 138%; 5% of sales in the prescription drugs segment;
- Paclitaxel-LENS (Paclitaxel; ATC «Antineoplastic and immunomodulating agents»); sales growth in comparison with H1 2011 amounted 8%; 5% of sales in the prescription drugs segment;
Total sales of the five products in the OTC drugs segment amounted to 99% of sales in the OTC drugs segment.
- Xilen (Xylometazoline; ATC «Respiratory system»); sales growth in comparison with H1 2011 amounted 35%; 49% of sales in the OTC drugs segment;
- Slabilen (Sodium picosulfate; ATC «Alimentary tract and metabolism»); sales growth in comparison with H1 2011 amounted 34%; 30% of sales in the OTC drugs segment;
- Motilak (Domperidone; ATC «Alimentary tract and metabolism»); sales growth in comparison with H1 2011 amounted 18%; 15% of sales in the OTC drugs segment;
- Vitasharm and Vitatress (ATC «Vitamins»); sales growth in comparison with H1 2011 amounted 271%; 4% of sales in the OTC drugs segment;
- Ginecotex vaginal tablets (Benzalkonium chloride; ATC «Urinary system&sex hormone»); 1% of sales in the OTC drugs segment.
Total sales of the five most popular traditional drugs by the results in H1 2011 amounted to RUR 13,4 million, or 97% of sales in the traditional drugs segment.
- Vero-Dexamethasone (Dexamethasone; ATC «Hormonal drugs»); 57% of sales in the traditional drugs segment;
- Pyridoxine hydrochloride (Pyridoxine; ATC «Alimentary tract and metabolism»); 24% of sales in the traditional drugs segment;
- Fluconazole (Fluconazole; ATC «General anti-infective systemic»); 11% of sales in the traditional drugs segment;
- Vero-Ciprofloxacin (Ciprofloxacin; ATC «General anti-infective systemic»); 3% of sales in the traditional drugs segment;
- Vero-Loperamide (Loperamide; ATC «Alimentary tract and metabolism»); 2% of sales in the traditional drugs segment.
In H1 2011 segment of Adhesive bandages and Cosmetic products had the following structure:
- Conventional bacterial adhesive bandages; 46% of sales in segment in H1 2011;
- Conventional reel adhesive bandages; 25% of sales in the segment in H1 2011;
- Therapeutic patches — pepper plasters, 12% of sales in the segment in H1 2011;
- Therapeutic patches — corn plasters, 16% of sales in the segment in H1 2011;
- Cosmetic products (Veromistin Silver, Daily, Flores); 1% of sales in the segment in H1 2011.
During the first half of 2011 Veropharm launched production and sales of the following new drugs:
- Vero-Netilmicin (Netilmicin; ATC «Antiinfectives for systemic use»);
- Vero-Asparaginase (Asparaginase; ÀÒÑ «Antineoplastic and immunomodulating agents»); new dosage – 10 000 ME ¹ 10;
- Veroklast (Zoledronic acid; ATC «Musculoskeletal system»); new dosage – 4mg/5 ml 5ml ¹ 1;
- Veromistin Silver (Myramistin; Remedy for intimate hygiene); new dosage – 50ml ¹ 1;
- Veromistin Daily (Myramistin; Remedy for hygienic treatment of the skin of hands and feet); new dosage – 50ml ¹ 1;
- Veromistin Flores (Myramistin; Remedy for oral hygiene); new dosage – 50ml ¹ 1.
In the first half of 2011 received registration certificate for the following products:
- The bandage Uniplast ointment;
- The bandage Uniplast wound sorbent;
Additionally, 14 drugs are currently at different stages of the registration process.
At the end of 1H 2011 Veropharm’s debt came to RUR 762.7 million, that represents less than 20% of net assets.
[1] according to management accounts of OJSC “Veropharm”
[2] % — percent of finished goods sales
[3] ATC – anatomico-therapeutico-chemical group.